Genocea Biosciences Inks $35M Series B
Vaccine developer Genocea Biosciences Inc. has raised $35 million in a second round of financing. New investors Johnson & Johnson Development Corporation, Skyline Ventures and MP Healthcare Venture Management contributed to the Series B round. Existing shareholders Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners and Morningside Ventures also participated. The financing will help support clinical development of the company’s therapeutic vaccine for herpes simplex virus type 2 infections. Genocea is based in Cambridge, Mass.
3 January 2011•3 mins read
